Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Healthy He/She should provide written informed consent He/She must be a healthy adult within 18-45 years of age (inclusive) He/She should have a Body mass index of ≥ 18.5 kg/m2 and ≤ 25 kg/m2, with body weight not less than 50 kg He/She should have a systolic blood pressure with upper limit of less than 140 mmHg and lower limit of more than or equal to 90 mm Hg. Similarly diastolic blood pressure with upper limit less than 90 mm Hg and lower limit more than or equal to 60 mmHg He/She must be of normal health as determined by medical history and physical examination performed within 21 days prior to the dosing of period 1 He/She should have a normal ECG, chest X-ray and vital signs Availability of a study volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent If study volunteer is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD), or abstinence. or is postmenopausal for at least 1 year. or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the study volunteers)  He/She is incapable of understanding the informed consent He/She has a history of hypersensitivity or idiosyncratic reaction to study drug or any other related drug He/She has any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. Study volunteers with a history of tuberculosis, epilepsy,asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for the study He/She smokes regularly more than ten cigarettes daily and has difficulty in abstaining from smoking for the duration of each study period He/She has taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past 30 days prior to dosing in first period He/She has a history of any psychiatric illness, which may impair the ability to provide written, informed consent He/She has a history of alcohol or substance abuse within the last 5 years He/She has clinically significant abnormal values of laboratory parameters He/She has participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months He/She is unable to or likely to be non-compliant with protocol requirements or restrictions